New levothyroxine formulation meeting 95-105% specification over the whole shelf-life: results from two pharmacokinetic trials.

CONCLUSIONS: The new formulation of L-T4 meets the most stringent potency specification guidelines, has been demonstrated to be bioequivalent to the current formulation and to show dosage form proportionality. The new formulation will enable patients to receive a dose fine-tuned to their medical needs, contributing to improved safety in the use of L-T4. PMID: 27718637 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/27718637?dopt=Abstract

Source: Current Medical Research and Opinion - October 13, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research

More News: Research